The COVID-19 pandemic has uniquely warped revenue for the big lab groups. Difficulty forecasting means Apax is in “no rush” to explore an exit while Cerba Healthcare may join Synlab in an IPO process, HBI can reveal. Synlab is reportedly on an IPO roadshow this week and Biogroup’s recent record-breaking raise on the bond market shows there’s an investor appetite.